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Insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease characterized by the destruction
of the insulin-secreting P cells found in the islets of Langerhans. Reduced P-cell mass results in overt
diabetes, requiring lifelong exogenous insulin administration and the possibility of numerous sequelae.
Incidence and development of IDDM depend upon a variety of genetic and nongenetic factors.
Environmental factors such as chemicals, diet, and infection are suspected to influence the
development of disease. This review describes the work performed to date to elucidate the role of
these environmental factors in IDDM. Key words: diet, drugs, environmental factors, infectious agents,
insulin-dependent diabetes mellitus. - Environ Health Perspect 1 07(suppl 5):777-781 (1999).
http.//ehpnetl.niehs.nih.gov/docs/1999/suppl-5/777-781kraine/abstract.html
Insulin-dependent diabetes mellitus (IDDM)
is an autoimmune disease characterized by
monocytic and lymphocytic infiltration of the
pancreatic islets. This insulitis results in the
gradual destruction of the insulin-secreting [B
cells found in the islets and an inability to
maintain blood glucose homeostasis. As a
result, diabetic patients must control blood
glucose levels via exogenous insulin adminis-
tration and are continually at risk for sec-
ondary complications due to fluctuations in
blood glucose. Sequelae such as retinopathy,
kidney failure, neuropathy, and strokes
decrease the diabetic patient's quality of life
and can eventually lead to premature death.
Risk for developing IDDM is strongly cor-
related with the expression of both major his-
tocompatibility complex (MHC) and a
number of non-MHC-related genes. However,
studies of disease incidence in identical twins
reveal only a 30-50% concordance rate (1).
This observation has been interpreted to mean
that environmental factors also influence the
disease process. A number of other findings
also support this notion. For example, individ-
uals who immigrate from a country with low
IDDM incidence to one with high incidence
adopt the higher disease rate of the new coun-
try (2). Furthermore, northern countries tend
to have higher frequencies of IDDM than do
southern countries (3), and the incidence of
IDDM is increasing in countries such as
Sardinia that have relatively stable genetic
backgrounds (4). There also appears to be an
inverse relationship between the development
of IDDM and socioeconomic development
(5). Finally, in animal models of IDDM, diet
and infection modulate disease susceptibility.
In light of these observations, investigators
have for years been attempting to identify
environmental factors that contribute to the
development of IDDM in humans. Various
synthetic drugs, diets, and infectious agents
have been implicated in the inhibition and/or
progression of IDDM. Unfortunately,
prospective studies following these factors are
rare and difficult to perform. Also, it is impor-
tant to differentiate between cases of acute-
onset childhood IDDM and juvenile IDDM.
Both require the administration of exogenous
insulin, but the mechanisms of islet destruc-
tion differ significantly between acute-onset
childhood and juvenile IDDM. During acute-
onset IDDM, insulin-secreting [ cells are
destroyed due to direct toxicity of an agent. [-
Cell destruction occurs quite rapidly and may
or may not involve an autoimmune compo-
nent. In contrast, juvenile-onset IDDM is the
result of monocytic- and lymphocytic-medi-
ated [B-cell destruction. This process reflects a
chronic inflammatory response during which
pancreatic islets are first infiltrated with
macrophages, dendritic cells, and T and B
lymphocytes, and [3 cells are progressively
destroyed. Based on observations made in
rodent models of spontaneous IDDM, T
lymphocytes are the primary mediators of [-
cell destruction. Although both types of
IDDM require the administration of insulin
for treatment, it is the juvenile diabetes that is
commonly referred to as type I IDDM.
This review summarizes the vast amount of
work involved in investigating the role of envi-
ronmental factors in the development of
IDDM. Potential mechanisms of induction of
IDDM by these factors will be reviewed. Both
acute-onset and autoimmune juvenile IDDM
will be covered, and the role of environmental
factors in the development of each will be
addressed. Studies performed in animal models,
as well as studies and observations from human





Molecular mimicry is based on two concepts
involving pathogenic antigen and reactive
lymphocytes (6). The first concept is based
on the observation that some pathogen pro-
teins share sequence or structural homology
with self-proteins. For example, the rubella
virus capsid protein shares homology with a
52-kD pancreatic islet antigen (7), and the
coxsackie virus P2-C protein shares homol-
ogy with another pancreatic antigen, glu-
tamic acid decarboxylase (GAD) (8,9). The
second concept is based on the fact that not
all self-reactive T (and B) lymphocytes are
deleted from the repertoire. They may
a) persist because of low affinity for antigen,
b) exist at a very low frequency, or c) react
with antigens that are normally sequestered
in tissues. In healthy individuals, these
autoreactive T lymphocytes normally exist
and are not pathogenic. It is hypothesized
that upon infection, pathogenic epitopes
that share homology with self-epitopes are
able to activate both pathogen-specific as
well as self-specific T lymphocytes. Although
self-specific T lymphocytes may bind epi-
topes with low affinity, the threshold for
activation may be lowered in the context of
an immune response to the pathogen.
Thus, self-reactive T lymphocytes are acti-
vated and may destroy [B cells expressing the
mimicked antigen.
Bystander Activation
In contrast to molecular mimicry, initial tissue
injury via bystander activation is not directly
antigen specific (10). For example, an infec-
tious agent may induce cell death, resulting in
the release of self-antigens that have previously
been sequestered. Consequently, these
antigens may activate existing autoreactive
T lymphocytes. In addition, the immune
response elicited by a bacterial or viral infec-
tion typically attracts antigen-presenting cells
and disrupts the cytokine balance [favoring a
predominantly T-helper (Th) 1 environment
(see "Immunoregulation")] at the site of infec-
tion/inflammation. Therefore, the body's nat-
ural response to pathogenic agents could
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indirectly provide an environment conducive
to the activation of autoreactive T lymphocytes
and development of autoimmune disease (see
"Immunoregulation").
Direct Celiular Injury
Pathogens that infect pancreatic islet cells may
induce IDDM by directly destroying the
insulin-secreting P cells. A critical mass of 1
cells may be destroyed after repeated infec-
tions or after a single severe infection resulting
in clinical IDDM.
Superantig
Superantigens are bacterial or viral products
that activate T lymphocytes expressing spe-
cific 5-chain variable gene (V%) families of the
T-cell receptor (TCR) (11). Superantigens
bind the side, not the cleft, of MHC mole-
cules, and interact with the Vp portion of the
TCR. Therefore, systemic or tissue-specific
infections may result in superantigen-induced
activation of self-reactive T lymphocytes
found in the periphery.
Imiunoregulation
IDDM is an autoimmune disease in which
pancreatic islet cells are infiltrated and
destroyed by autoreactive CD4+ and CD8+ T
lymphocytes. CD4+ Th lymphocytes (and
CD8+ lymphocytes) are divided into subsets
based on the type of cytokines secreted and
the type of immune response mediated (12).
A number of studies have demonstrated that
Thl cells are the primary mediators of 1-cell
destruction leading to disease (13). Thl cells
promote inflammatory responses and are
characterized by the production of interferon
(IFN)-y and interleukin (IL)-2. In contrast,
Th2 cells confer protection from IDDM in
animal models. Th2 cells promote humoral
immune responses and secrete IL-4 and IL-
10. Whereas IFN-,y and IL-12 promote the
development of Thl cells, IL-4 is necessary
for differentiation of Th2 cells. Furthermore,
cytokines IFN-y (secreted by Thl cells) and
IL-4 and IL-10 (from Th2 cells) downregu-
late Th2 and Thl effector cell differentiation
and function, respectively. Thus, the Th cell
and cytokine response elicited by an environ-
mental agent may be a factor contributing to




Animal stdies. Numerous animal models of
drug-induced IDDM exist. Most of these
drug regimens mediate acute-onset IDDM,
making them especially useful models to study
novel modalities of treatment for established
disease. Streptozotocin (STZ) is an antibiotic
and chemotherapeutic agent commonly used
to induce IDDM in rodents. A single high
dose of STZ initiates P-cell necrosis by 4 hr,
with blood glucose levels peaking (and
remaining high) at 1-2 days (14). The
mechanism of high-dose STZ-induced acute-
onset IDDM appears to be through damage
to the mitochondria of P cells (15). When
STZ is administered in multiple low doses,
P-cell necrosis begins by day 5 after the final
injection, with blood glucose levels peaking at
1 week or later (after the final injection). This
treatment regime is thought to induce a cell-
mediated immune response, as 5-cell destruc-
tion continues after the STZ has been deared
from the bloodstream (14). Therefore, the
diabetes induced with multiple doses of STZ
may more closely resemble the autoimmune
process associated with juvenile-onset IDDM.
A second drug, alloxan, is used to induce
IDDM in animal models. Alloxan is toxic to
,B cells for two reasons (16). First, it rapidly
accumulates in islet cells. Second, upon oxi-
dation, it produces reactive oxygen species
and peroxides that are toxic to t cells.
Consequently, the acute-onset IDDM
induced by alloxan is primarily due to the
accumulation of toxic byproducts in 1 cells.
Cyclophosphamide is the third drug
commonly used to induce IDDM in animal
models. Two injections of 200 mg/kg at 14-
day intervals will induce IDDM in most
mice within 2-3 weeks (17,18). P-Cell
destruction is thought to be due to the elimi-
nation of regulatory T lymphocytes with
concomitant upregulation of Thl responses
(17,18). mRNA expression of IFN-,y (a Thl
cytokine) and nitric oxide synthase is also
enhanced in islet-infiltrating lymphocytes
when cyclophosphamide is used to accelerate
IDDM induction in the nonobese diabetic
(NOD) mouse model (19).
Human studies. Though there are
numerous reports of drug-induced IDDM in
human patients, each case must be examined
to determine its support of a drug or chemical
agent as a true environmental factor influenc-
ing the disease process. For example, Vacor
[1-(4-nitrophenyl)-3-(3-pyridylmethyl) urea]
is probably the dearest example of a chemical
that induces IDDM (20). It is a rodenticide
that specifically destroys 1 cells through the
inhibition of mitochondrial complex I func-
tion (21). Although Vacor clearly is toxic to
P3 cells, it is not considered to be an important
environmental factor contributing to disease
incidence, as it is not normally ingested and
has no clinical benefit to humans. It was, in
fact, removed from the market after numerous
accidental poisonings and suicide attempts in
the late 1970s.
IDDM may also result from side effects of
a drug administered long term, as in cases of
posttransplantation immunosuppression or
the treatment of cancer. In these cases,
patients tend to be extremely ill and are often
administered multiple medications that may
interact with one another. As a result, it is dif-
ficult to determine whether the IDDM that
may develop is a result of a) the underlying
disease state, b) a single medication or a com-
bination of medications, and/or c) the med-
ication(s) involved. One such case that has
recently received much attention is the use of
tacrolimus (FK 506 or PrograO, a macrolide
antibiotic often used as part of an immuno-
suppressive drug regimen. The diabetogenic
effect of tacrolimus depends on numerous
factors, including dose (22,23), patient age
(24-26), and the dose of corticosteroids
administered as part of the regimen (24).
Corticosteroids alone have also been impli-
cated as diabetogenic (because of alterations
in glucose metabolism), requiring long-term
insulin administration in a small number of
cases (27,28). Further complicating the
situation, some patients regain insulin inde-
pendence when tacrolimus and/or corticos-
teroid doses are reduced or discontinued
(24-26), whereas others do not. This also
appears to be dose dependent. The mecha-
nism by which tacrolimus causes IDDM has
not been fully elucidated, but possibilities
include reduced insulin mRNA synthesis and
inhibition of insulin release from pancreatic
P cells, and an increase in peripheral insulin
resistance (29,30). Other chronic medica-
tions that fit this category include chemother-
apeutic agents such as L-asparaginase (31,32)
and IFN-a (33). Although implicated in the
development of IDDM, no direct evidence
for the involvement of these latter drugs or
for the potential mechanism of action has
been reported.
Another common occurrence is that a
single drug is implicated in the development of
IDDM but only in a small number of cases.
For example, pentamidine treatment for
Pneumoystis carinii pneumonitis has led to the
induction of IDDM following P-cell destruc-
tion (34). Although the involvement of the
drug is dear, the low incidence ofIDDM and
the specific patient population involved also
indicate that pentamidine is not a common
cause of IDDM. Finally, there are occasional
reports of various drugs such as isotretinoin
(35) causing IDDM. It is important to note,
however, that it is not known whether in
these cases the drug had a direct role in the
initiation or progression of the disease or if
disease onset were simply coincidental with
drug administration.
All cases of drug- or chemical-induced
IDDM in humans to date appear to be due
to rapid destruction of pancreatic P cells
and are classified as acute-onset IDDM.
Furthermore, comparison of the structure
and known mechanism of action of these
drugs/chemicals does not reveal any unifying
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FACTORS THAT INFLUENCE IDDM
features that may in turn correlate with
disease progression.
Food/Diet
Animal studies. Although the role of diet has
been studied in animal models for more than
15 years, data on the influence of food con-
stituents remain incomplete. A recent review
by Akerblom and Knip (36) thoroughly cov-
ers the controversial role of diet and food
products in the development of IDDM.
Studies on the effect of diet in the BB rat
have shown that plant-based diets are the
most diabetogenic, possibly due to wheat and
soy products (37). The ,B cells of diabetic
mice fed such diets exhibit increased expres-
sion ofMHC I molecules and infiltration of
Th cells of the Thl phenotype (37). Cow's
milk proteins, N-nitroso compounds, and
gluten are other constituents that may affect
the incidence of IDDM in animal models.
However, some food components such as
casein promote disease in the NOD mouse
model but have no deleterious effect in the
BB rat. As both rodent strains provide excel-
lent models of spontaneous autoimmune
IDDM, such contradictions make determina-
tion of the true role of dietary factors in
disease difficult.
Human studies. Studying the effect of
diet in humans is far more difficult than in
animal models for the obvious reason that the
human diet is usually not controlled for
extended periods of time, let alone from birth.
Studies of the effect of cow's milk, human
breast milk, N-nitroso compounds, gluten,
bovine serum albumin, fat, and protein on the
development of IDDM are numerous, but
none of these factors proven to play a direct
role in the disease process.
Infectious Environmental
Factors
VirlI and Bacterial Infections
Animal studies. The role of viruses in the
development ofIDDM has been and contin-
ues to be a topic of great interest. The major-
ity of animal studies involving infectious
agents have been based upon induction of
disease following challenge with a given
virus. These studies do not necessarily reflect
the development of spontaneous IDDM but
nevertheless may provide insight into mecha-
nisms by which viral infection can mediate
IDDM. In addition, viral-induced models
may more closely reflect acute-onset IDDM
and not autoimmune-mediated juvenile-
onset disease. Furthermore, spontaneous viral
and bacterial infections in the NOD mouse
model are known to protect mice from devel-
oping the disease. Therefore, the effect of
infectious agents in diabetic animal models is
still controversial.
Coxsackie-B4 (CVB) (38,39) and
encephalomyocarditis M (40) are two viruses
that have been used to induce IDDM in
rodents. Studies in CD-1 mice challenged
with a diabetogenic strain of CVB have
shown that lymphocytes can destroy acutely
infected islet cells, and macrophages are able
to lyse chronically infected islets. This results
in prolonged hyperglycemia, which reverts to
normoglycemia within 6-12 months in most
cases (38). Destruction of islets by macro-
phages can occur in the absence of detectable
viral protein expression (although viral RNA
is detectable), suggesting that the develop-
ment of IDDM is related to prolonged pres-
ence of viral RNA in the pancreas. In an
earlier study, it was observed that a) CVB
infection is mouse strain specific, b) a 3-cell
tropic virus is essential, and c) in most cases
IDDM is transient (39). Studies using the
encephalomyocarditis virus to induce IDDM
are also mouse strain specific and result in a
self-limiting disease.
Several groups have developed transgenic
mouse models using genes encoding viral
antigens and subsequent infection with the
corresponding virus in an attempt to induce
IDDM [reviewed in von Herrath et al. (41)].
In these models, expression of the viral anti-
gen gene is localized to 1 cells via the rat
insulin promoter. Studies of the immune
response after challenge with virus have pro-
vided information as to the contribution of
T-lymphocyte precursor frequency, thymic
negative selection, local antigen concentra-
tion, and cytokine milieu in the development
of IDDM. All the mice develop IDDM
because of an autoimmune process mediated
by T lymphocytes, similar to the human juve-
nile onset disease. Despite the usefulness of
these transgenic mouse models, they do not
provide evidence for a direct role for viruses
in the normal development ofIDDM.
The role of bacterial infections in the
development of IDDM has been studied
through observation of disease incidence in
NOD mouse colonies (incidence decreases
with bacterial infection) and via administra-
tion of bacterial products in adjuvants or
immunizations. Administration of complete
Freund's adjuvant (CFA) does not prevent
insulitis but does prevent overt IDDM in
NOD mice. Animals protected from disease
have decreased mRNA expression of Thi -type
cytokines (42,43), increased anti-GAD67 anti-
bodies (GAD is an autoantigen known to be
important in the development of IDDM), and
Th2 cytokine production (44). It is thought
that Mycobacterium tuberculosis found in CFA
is responsible for the protective effect of the
adjuvant via immune deviation from a pre-
dominandy ThI to a Th2 cytokine response.
A second example of protection from
IDDM that implicates a bacterial product
involves the bacille Calmette-Guerin (BCG)
vaccine, which contains Mycobacterium bovis.
BCG protects against IDDM when adminis-
tered within 3 days after cyclophosphamide
treatment (before the onset of insulitis in this
model) (45). BCG is also thought to protect
via induction of immune deviation; protected
NOD mice exhibit restored anti-GAD67 anti-
body production and increased IL-4:IFN-y
ratios (45).
Human studies. In human patients,
numerous viruses have a role in the develop-
ment of IDDM. The mumps virus, cyto-
megalovirus, Epstein Barr virus, rubella virus,
coxsackie viruses, and retroviruses have all
been found in patients at the time of diagno-
sis of IDDM [reviewed in von Herrath et al.
(41)]. However, it is difficult to determine if
a viral infection is coincidental with the onset
of IDDM or has actively contributed to the
disease process that may have been ongoing
for several years prior to any clinical manifes-
tation. Therefore, the precise role viruses play
(if any) in the development of IDDM is not
known. For example, viruses may initiate the
destruction of 1B cells or promote progression
of the diabetogenic response. To gain insight
into these issues, it is necessary to follow a
sufficient number of genetically susceptible
individuals to determine whether a correla-
tion between IDDM diagnosis and viral
infections can be established from birth (and
possibly in utero). Currently, this type of
prospective study is extremely difficult to per-
form. Retrospective studies of viral infections,
although easier to perform, are typically unre-
liable. Many infections may be subclinical and
thus not recorded, and some viruses have the
ability to persist in the body for several years.
Together, these factors make an assessment of
the role of viruses in the development of
IDDM highly problematic.
Rubella, coxsackie, and retroviruses have
been studied extensively in recent years. To
date, rubella is the only virus for which con-
clusive evidence exists showing that infection
significantly increases the risk of developing
IDDM. In a study of 50 patients with con-
genital rubella, 20% of patients developed
IDDM between 18 months and 33 years of
age (46). Studies in which rabbits were
infected in utero confirmed histologic changes
in pancreatic 1 cells due to the rubella virus.
It is unknown whether P-cell destruction is
due to direct damage by the virus, or if the
virus induces immunologic changes that indi-
rectly destroy the islet cells. The fact that
patients as young as 18 months develop
IDDM would suggest a direct cytopathic
effect, whereas some patients develop the dis-
ease in a more progressive manner (remaining
insulin-independent until 33 years of age),
suggesting indirect, possibly autoimmune,
mechanisms of damage. Finally, despite an
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established effect on the development of
IDDM, rubella virus nonetheless does not
appear to be a major environmental factor
influencing disease incidence.
CVB is an enterovirus that has been impli-
cated in the development of IDDM, based on
a number of observations [reviewed in Hoyt
et al. (47)]. CVB infects pancreatic P cells in
vitro and in vivo and has been detected in
P cells after acute and fatal cases of IDDM.
Also, IgG and IgM antibodies specific for
CVB and CVB-specific RNA have been
found in the sera of newly diagnosed diabet-
ics. Seasonal variation ofCVB infection has in
some regions paralleled incidence of IDDM.
A prospective study found relatively more fre-
quent enteroviral infections during the first
trimester of pregnancy in mothers whose chil-
dren developed IDDM before 3 years of age,
with no difference in children developing the
disease between 4 and 6 years of age. In the
same study, the group of diabetic siblings had
a significantly greater number of enterovirus
infections than did nondiabetic siblings (48).
Molecular mimicry, based on homology
between the 2C protein of CVB and GAD,
has been proposed as one mechanism by
which CVB may induce IDDM. Recently,
however, Horwitz et al. (49) used three mouse
models (NOD, B1O.H2g7, BDC2.5) to eluci-
date the mechanism by which CVB may
induce IDDM. No spontaneous immune
response to CVB cross-reactive GAD peptides
was observed in NOD or B1O.H2g7 mice
infected with CVB, which in turn did not
develop IDDM. Both these strains carry the
diabetes-associated MHC class II allele I-Ag7,
which presents GAD peptides to autoreactive
CD4+ T lymphocytes. If CVB induces
IDDM via molecular mimicry, one would
expect enhanced anti-GAD T-cell reactivity
and subsequent development of IDDM in
infected mice. BDC2.5 mice that are trans-
genic for a TCR specific for an unknown pan-
creatic autoantigen (the majority of the
T lymphocytes are specific for this f-cell
autoantigen) exhibit an enhanced onset of
IDDM following infection with CVB. These
results suggest that the CVB infection may
induce IDDM via a bystander mechanism.
Recently, retroviral superantigens have
been implicated in the development of
IDDM. Pancreatic enrichment of the V37
family was observed in two IDDM patients,
suggesting superantigen involvement (50).
The superantigen implicated in those two
cases was encoded by an endogenous retro-
virus related to mouse mammary tumor
viruses (51). The authors propose a two-step
model in which systemic polyclonal activa-
tion of V17-restricted T cells is triggered by
expression of the superantigen in the context
of MHC class II. Subsequently, autoreactive
T cells of the activated subset may initiate
organ-specific destruction of the pancreas.
Though the endogenous retrovirus has been
identified, the mechanism of tissue destruc-
tion and role in disease progression as the ini-
tial trigger, final precipitator, or simply as a
marker of disease remains unclear.
Summary
Although environmental factors have been
implicated in the development of IDDM for
years, a unifying influence remains elusive.
Because of the polygenic nature of IDDM,
such unifying factors may not exist. Specific
environmental factors may influence individ-
uals quite differently depending upon the
genotype of that individual. Designing
prospective studies that take into account
genetic background of individuals also
remains an obstacle to obtaining accurate
data on the role of environmental agents. If
these agents do influence the development of
IDDM, it must be determined whether they
function as initiators of disease, promote pro-
gression of an ongoing diabetogenic response,
or play multiple roles in the disease process.
Clearly, direct identification of environmental
factors and their precise role in the disease
process will be extremely useful in prevention
and treatment ofIDDM.
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